The post Humana And Mark Cuban’s Cost Plus Drugs Working On Partnership appeared on BitcoinEthereumNews.com. Cost Plus Drugs founder Mark Cuban (Center) speaks at the annual Forbes Healthcare Summit Thursday, December 4th in New York with Humana chief executive officer Jim Rechtin (right) and Bruce Japsen, Forbes Senior healthcare contributor. Jamel Toppin Humana, one of the nation’s largest health insurers for older adults, and Mark Cuban’s Cost Plus Drugs are discussing ways to partner to lower the cost of prescription drugs for U.S. employers. Humana chief executive officer Jim Rechtin and Cuban, the billionaire entrepreneur who co-founded Cost Plus Drugs, disclosed the potential for such a partnership Thursday at the annual Forbes Healthcare Summit. The two, who were on the same panel, said they were working together on ways to improve patient experience at the pharmacy. The initial effort for Humana and Cost Plus Drugs will be in the area of direct-to-employer programs that bypass traditional pharmacy benefit management companies, Cuban said. “We’re talking to CenterWell,” Cuban said of Humana’s CenterWell healthcare services business, which includes a specialty pharmacy. “I would say we are treating the whole person plus their wallet.” Such a deal could be a big win for Cost Plus Drugs given Humana has more than 8 million health plan enrollees. Of those, more than 5 million are enrolled in Humana’s Medicare Advantage plans, which are popular choices for coverage among adults who are 65 years of age and older. “They have volume,” Cuban said during the panel, which was held at NYU Langone Health in Manhattan. Details of the partnership weren’t disclosed, and it’s and still in early stages, according to sources close to both companies. Rechtin said Humana is working on ways to simplify the pharmacy experience and take unnecessary steps out of the prescription process between the manufacturer and the ability of patients to get their medications. It’s the latest… The post Humana And Mark Cuban’s Cost Plus Drugs Working On Partnership appeared on BitcoinEthereumNews.com. Cost Plus Drugs founder Mark Cuban (Center) speaks at the annual Forbes Healthcare Summit Thursday, December 4th in New York with Humana chief executive officer Jim Rechtin (right) and Bruce Japsen, Forbes Senior healthcare contributor. Jamel Toppin Humana, one of the nation’s largest health insurers for older adults, and Mark Cuban’s Cost Plus Drugs are discussing ways to partner to lower the cost of prescription drugs for U.S. employers. Humana chief executive officer Jim Rechtin and Cuban, the billionaire entrepreneur who co-founded Cost Plus Drugs, disclosed the potential for such a partnership Thursday at the annual Forbes Healthcare Summit. The two, who were on the same panel, said they were working together on ways to improve patient experience at the pharmacy. The initial effort for Humana and Cost Plus Drugs will be in the area of direct-to-employer programs that bypass traditional pharmacy benefit management companies, Cuban said. “We’re talking to CenterWell,” Cuban said of Humana’s CenterWell healthcare services business, which includes a specialty pharmacy. “I would say we are treating the whole person plus their wallet.” Such a deal could be a big win for Cost Plus Drugs given Humana has more than 8 million health plan enrollees. Of those, more than 5 million are enrolled in Humana’s Medicare Advantage plans, which are popular choices for coverage among adults who are 65 years of age and older. “They have volume,” Cuban said during the panel, which was held at NYU Langone Health in Manhattan. Details of the partnership weren’t disclosed, and it’s and still in early stages, according to sources close to both companies. Rechtin said Humana is working on ways to simplify the pharmacy experience and take unnecessary steps out of the prescription process between the manufacturer and the ability of patients to get their medications. It’s the latest…

Humana And Mark Cuban’s Cost Plus Drugs Working On Partnership

2025/12/05 05:36

Cost Plus Drugs founder Mark Cuban (Center) speaks at the annual Forbes Healthcare Summit Thursday, December 4th in New York with Humana chief executive officer Jim Rechtin (right) and Bruce Japsen, Forbes Senior healthcare contributor.

Jamel Toppin

Humana, one of the nation’s largest health insurers for older adults, and Mark Cuban’s Cost Plus Drugs are discussing ways to partner to lower the cost of prescription drugs for U.S. employers.

Humana chief executive officer Jim Rechtin and Cuban, the billionaire entrepreneur who co-founded Cost Plus Drugs, disclosed the potential for such a partnership Thursday at the annual Forbes Healthcare Summit. The two, who were on the same panel, said they were working together on ways to improve patient experience at the pharmacy.

The initial effort for Humana and Cost Plus Drugs will be in the area of direct-to-employer programs that bypass traditional pharmacy benefit management companies, Cuban said.

“We’re talking to CenterWell,” Cuban said of Humana’s CenterWell healthcare services business, which includes a specialty pharmacy. “I would say we are treating the whole person plus their wallet.”

Such a deal could be a big win for Cost Plus Drugs given Humana has more than 8 million health plan enrollees. Of those, more than 5 million are enrolled in Humana’s Medicare Advantage plans, which are popular choices for coverage among adults who are 65 years of age and older. “They have volume,” Cuban said during the panel, which was held at NYU Langone Health in Manhattan.

Details of the partnership weren’t disclosed, and it’s and still in early stages, according to sources close to both companies.

Rechtin said Humana is working on ways to simplify the pharmacy experience and take unnecessary steps out of the prescription process between the manufacturer and the ability of patients to get their medications.

It’s the latest effort by Humana to innovate and grow a business in the pharmacy space. Humana’s CenterWell expanded into the fast-growing and lucrative business of direct-to-patient specialty pharmacy as demand grows for popular GLP-1 weight loss drugs.

Humana’s CenterWell healthcare services business said it would expand beyond its traditional home-delivery pharmacy services business and will begin filling and shipping orders for the popular GLP-1 weight loss drug Wegovy that are prescribed through three telehealth companies: Hims & Hers Health, Inc., LifeMD and Ro.

Source: https://www.forbes.com/sites/brucejapsen/2025/12/04/humana-mark-cubans-cost-plus-drugs-working-on-partnership/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

QQQ short term cycle nearing end; pullback likely to attract buyers [Video]

QQQ short term cycle nearing end; pullback likely to attract buyers [Video]

The post QQQ short term cycle nearing end; pullback likely to attract buyers [Video] appeared on BitcoinEthereumNews.com. The short-term Elliott Wave outlook for the Nasdaq 100 ETF (QQQ) indicates that the cycle from the April 2025 low remains active. Wave (4) of the ongoing impulse concluded at 580.27, and the ETF has since resumed its upward trajectory. To confirm continuation, price must break above the prior wave (3) peak recorded on 30 October at 638.41. The rally from the 21 November wave (4) low has matured and is expected to complete soon, reflecting the natural rhythm of the Elliott Wave sequence. The advance from wave (4) has unfolded as a five-wave impulse. Within this structure, wave ((i)) ended at 586.25, followed by a corrective pullback in wave ((ii)) that terminated at 580.36. From there, the ETF nested higher. Wave (i) of the next sequence ended at 596.98, while wave (ii) pulled back to 589.44. Momentum carried wave (iii) to 606.76, before wave (iv) corrected to 597.32. The final leg, wave (v), reached 619.51, completing wave ((iii)) at a higher degree. A subsequent pullback in wave ((iv)) ended at 612.13. Looking ahead, wave ((v)) of 1 is expected to finish soon. Afterward, a corrective wave 2 should unfold, addressing the cycle from the 21 November low before the ETF resumes higher. In the near term, as long as the pivot at 580.27 remains intact, dips are anticipated to find support in a 3, 7, or 11 swing sequence, reinforcing prospects for further upside. Nasdaq 100 ETF (QQQ) 30-minute Elliott Wave chart from 12.5.2025 Nasdaq 100 ETF Elliott Wave [Video] Source: https://www.fxstreet.com/news/qqq-short-term-cycle-nearing-end-pullback-likely-to-attract-buyers-video-202512050323
Share
BitcoinEthereumNews2025/12/05 11:40